



US PATENT & TRADEMARK OFFICE

PATENT BIBLIOGRAPHIC DATABASE

Help

Boolean

Advanced

Number

Order Copy

PTDLs

Searching ALL...

[Search Summary]

Results of Search in ALL for:**TTL/non-human:** 59 patents.**Hits 1 through 50 of 59**

Final 9 Hits

Submit As

Refine Search

TTL/"non-human"

Pat. No. Title

1. 6,025,540 Transgenic *non-human* mammals producing EC-SOD protein in their milk
2. 6,023,010 Transgenic *non-human* animals depleted in a mature lymphocytic cell-type
3. 5,994,616 Targeted synthesis of protein in mammary gland of a *non-human* transgenic mammal
4. 5,993,779 Method for producing *non-human* animal having spinal cord injury
5. 5,989,604 Xylitol-containing *non-human* foodstuff and method
6. 5,981,579 Use of nitrovasodilators for treatment of disease or stress conditions in a *non-human* mammal
7. 5,965,789 Engineering protein posttranslational modification by PACE/furin in transgenic *non-human* mammals
8. 5,965,788 Transgenic *non-human* mammal comprising a rabbit WAP promoter
9. 5,955,644 Ku deficient cells and *non-human* transgenic animals
10. 5,955,056 Mutagenesis testing using transgenic *non-human* animals carrying test DNA sequences
11. 5,943,983 *Non-human* primate research support tilt table
12. 5,932,780 Transgenic *non-human* animal assay system for anti-cholinesterase substances
13. 5,912,410 Transgenic *non-human* mice displaying the amyloid-forming pathology of alzheimer's disease
14. 5,905,185 Protein C production in *non-human* transgenic mammals
15. 5,892,070 Transgenic *non-human* mammals producing oligosaccharides and glycoconjugates
16. 5,891,698 Oligosaccharides and glycoproteins produced in milk of transgenic *non-human* mammals
17. 5,877,397 Transgenic *non-human* animals capable of producing heterologous antibodies of various isotypes
18. 5,874,299 Transgenic *non-human* animals capable of producing heterologous

18. antibodies
19. 5,859,312 Transgenic *non-human* animals having targeting endogenous lymphocyte transduction genes and cognate human transgenes
20. 5,850,000 Transgenic *non-human* mammals comprising a bovine 5' flanking regulatory sequence
21. 5,849,999 Transgenic *non-human* mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior
22. 5,831,141 Expression of a heterologous polypeptide in mammary tissue of transgenic *non-human* mammals using a long whey acidic protein promoter
23. 5,827,694 DNA encoding *non-human* animal interferons, vectors and hosts therefor, and recombinant production of IFN polypeptides
24. 5,824,287 Mutagenesis testing using transgenic *non-human* animals carrying test DNA sequences
25. 5,814,318 Transgenic *non-human* animals for producing heterologous antibodies
26. 5,814,300 Gene-targeted *non-human* mammals deficient in the SOD-1 gene
27. 5,811,632 *Non-human* mammalian model for human papillomavirus-induced disease
28. 5,789,650 Transgenic *non-human* animals for producing heterologous antibodies
29. 5,770,429 Transgenic *non-human* animals capable of producing heterologous antibodies
30. 5,763,739 Transgenic *non-human* mammals producing BSSL variants
31. 5,750,826 Bradykinin B2 receptor modified transgenic *non-human* animals
32. 5,750,176 Transgenic *non-human* mammal milk comprising 2'-fucosyl-lactose
33. 5,716,817 Transgenic *non-human* mammals that express human BSSL/CEL
34. 5,698,767 Human immune system in *non-human* animal
35. 5,667,766 *Non-human* animal model of a human airway, methods of use
36. 5,661,016 Transgenic *non-human* animals capable of producing heterologous antibodies of various isotypes
37. 5,633,425 Transgenic *non-human* animals capable of producing heterologous antibodies
38. 5,631,153 Cells and *non-human* organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
39. 5,627,059 Cells and *non-human* organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
40. 5,625,128 *Non-human* animal model of a human airway
41. 5,625,126 Transgenic *non-human* animals for producing heterologous antibodies
42. 5,602,307 *Non-human* animal having predefined allele of a cellular adhesion gene
43. 5,602,301 *Non-human* mammal having a graft and methods of delivering protein to myocardial tissue
44. 5,589,155 Mutagenesis testing using transgenic *non-human* animals carrying

44. test DNA sequences
45. 5,569,825 Transgenic *non-human* animals capable of producing heterologous antibodies of various isotypes
46. 5,545,806 Ransgenic *non-human* animals for producing heterologous antibodies
47. 5,543,131 HIV-2 strains capable of infecting humans and *non-human* primates, and infected *non-human* primates with immune system disease
48. 5,510,099 Mutagenesis testing using transgenic *non-human* animals carrying test DNA sequences
49. 5,487,992 Cells and *non-human* organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
50. 5,476,996 Human immune system in *non-human* animal

Final 9 Hits

Search ME

Refine Search

TTL/"non-human"

Search Summary**TTL/non-human:** 60 occurrences in 59 patents.

Search Time: 0.05 seconds.





US PATENT & TRADEMARK OFFICE

PATENT BIBLIOGRAPHIC DATABASE

[Help](#)[Boolean](#)[Advanced](#)[Number](#)[Order Copy](#)[PTDLs](#)[\[Search Summary\]](#)**Results of Search in ALL for:****TTL/non-human:** 59 patents.**Hits 51 through 59 of 59**[Prev: 50 Hits](#)[Start At:](#) [Refine Search](#)

TTL/"non-human"

Pat. No. Title

51. 5,447,953 Biomasses to treat *non-human* animals
52. 5,420,264 *Non-human* primate CD4 polypeptides, human CD4 molecules capable of glycosylation, fragments thereof, fusion proteins thereof, genetic sequences thereof, and the use thereof
53. 5,347,075 Mutagenesis testing using transgenic *non-human* animals carrying test DNA sequences
54. 5,316,941 *Non-human* carbonyl hydrolase mutants, DNA sequences and vectors encoding same and hosts transformed with said vectors
55. 5,182,204 *Non-human* carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors
56. 5,087,571 Method for providing a cell culture from a transgenic *non-human* mammal
57. 5,008,183 Assay system for detecting antibody and a method of producing *non-human* immune antibody
58. 4,777,245 *Non-human* primate monoclonal antibodies and methods
59. 4,736,866 Transgenic *non-human* mammals

[Prev: 50 Hits](#)[Start At:](#) [Refine Search](#)

TTL/"non-human"

Search Summary

TTL/non-human: 60 occurrences in 59 patents.

Search Time: 0.05 seconds.





US PATENT & TRADEMARK OFFICE

PATENT BIBLIOGRAPHIC DATABASE

Help

Full Text

Boolean

Advanced

Number

Order Copy

PTOLs



(34 of 59)

United States Patent

5,698,767

Wilson, et. al.

Dec. 16, 1997

Human immune system in *non-human* animal

Abstract

Laboratory *non-human* animals in which the immune system of a donor is induced in and thrives in vivo and expresses the immune response of the donor animal in a recipient *non-human* animal of a different species than the donor, and wherein malignant immune system cells of the donor can be induced in the recipient *non-human* animal by injection of non-malignant donor into the recipient are disclosed.

Inventors: Wilson; Darcy B. (La Jolla, CA); Mosier; Donald E. (Del Mar, CA).

Assignee: Lidak Pharmaceuticals (La Jolla, CA).

Appl. No.: 543,449

Filed: Oct. 16, 1995

Related U.S. Application Data

Continuation of (including streamline cont.) Ser. No. 57,006, May 4, 1993, Pat. No. 5,476,996, which is a continuation of Ser. No. 425,047, Oct. 23, 1989, abandoned, which is a continuation-in-part of Ser. No. 241,590, Sept. 8, 1988, abandoned, which is a continuation-in-part of Ser. No. 207,273, Jun. 14, 1988, abandoned.

Intl. Cl.:

A61K 35/00, A61K 48/00, C12N 15/00

Current U.S. Cl.:

800/11; 424/9.1; 424/93.1; 424/93.7; 424/93.71;
424/534; 424/577; 424/578; 435/325

Field of Search:

800/2, DIG. 2, DIG. 5; 424/93.71, 93.7, 93.1, 9.1,
534, 577, 578; 435/240.2, 325

References Cited | [Referenced By]

U.S. Patent Documents

4,624,917

Nov., 1986

Sugimoto

Other References

Bosma et al., "A severe combined immunodeficiency mutation in the mouse", Nature 301: 527-530 (1983).

Cannon et al., "Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID-hu chimeric mice", J. Clin. Invest. 85(4): 1333-1337 (1990).

Custer, R.P. "Severe combined immunodeficiency in the mouse pathology reconstitution neoplasms", *Am. J. Pathol.* 120(3): 464-477 (1985).

Czitrom et al., "The function of antigen-presenting cells in mice with severe combined immunodeficiency", *Immunol.* 134(4): 2276-2280 (1985).

Dorshkind et al., "Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease", *J. Immunol.* 132: 1804-1808 (1984).

Dorshkind et al., "Natural killer cells are present in mice with severe combined immunodeficiency", *J. Immunol.* 134: 3798-3801 (1985).

Dorshkind et al., "Lymphoid bone marrow cultures can reconstitute heterogeneous B and T cell-dependent responses in severe combined immunodeficiency mice", *J. Immunol.* 137: 3457-3463 (1986).

Garcia et al., "B-cell lymphoma in severe combined immunodeficiency not associated with the Epstein-Barr virus", *Cancer* 60: 2941-2947 (1987).

Kersey et al., "Relationship of immunodeficiency to lymphoid malignancy", *Pediatric Infect. Dis. J.* 7(31): S10-S12 (1988).

Lauzon et al., "An expanded population of natural killer cells in mice with severe combined immunodeficiency lack rearrangement and expression of T cell receptor genes", *J. Exp. Med.* 164(5): 1797-1802 (1986).

Louie et al., "Immunodeficiency and the pathogenesis of non-Hodgkin's lymphoma", *Seminars in Oncology* 7(3): 267-284 (1980).

McCune et al., "The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function", *Science* 241: 1632-1639 (1988).

Mosier et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency", *Nature* 335: 256-259 (1988).

Mosier, D.E., *J. Clin. Immunol.* "Immunodeficient mice xenografted with human lymphoid cells: New models for in vivo studies of human immunobiology and infectious diseases", *J. Clin. Immunol.* 10: 185-191.

Namikawa et al., "Infection of the SCID-hu mouse by HIV-1", *Science* 242: 1684-1686 (1988).

Perryman et al., "Evaluation of fetal liver cell transplantation for immuno-reconstitution", *Clin. Immunol. Immunopath.* 23(1): 1-9 (1982).

Pinkert et al., "Tissue-specific, inducible and functional expression of the E.alpha.(^d) MHC class II gene in transgenic mice", *The EMBO J.* 4: 2225-2230 (1985).

Polmar et al., "Long-term immunological reconstitution by peripheral blood leukocytes in severe combined immune deficiency disease", *Clin. Exp. Immunol.* 64: 518-525 (1986).

Reddy et al., "Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency", *Cancer Res.* 47: 2456-2460 (1987).

Saxon et al., "Limited B cell repertoire in severe combined immunodeficiency mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans", J. Clin. Invest. 87: 658-665 (1991).

Shearer et al., "Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency", N. Engl. J. Med. 312: 1151-1159 (1985).

Wade et al., "Characterization of xenogeneic mouse-to-rat bone marrow chimeras. I. Examination of hematologic and immunologic function", Transplantation 44(1): 88-92 (1987).

Ware et al., "Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID)", J. Immunol. Meth. 85: 353-361 (1985).

Primary Examiner: Chambers; Jasmine C.

Assistant Examiner: Schmuck; Jill

Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear, LLP

11 Claims, 7 Drawing Figures



(34 of 59)



US PATENT & TRADEMARK OFFICE

PATENT BIBLIOGRAPHIC DATABASE

Help

Full Text

Boolean

Advanced

Number

Order Copy

PTOLs



(43 of 59)

United States Patent
Field

5,602,301
Feb. 11, 1997

***Non-human* mammal having a graft and methods of delivering protein to myocardial tissue**

Abstract

Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart.

Inventors: **Field; Loren J.** (Indianapolis, IN).

Assignee: **Indiana University Foundation** (Bloomington, IN).

Appl. No.: **153,664**

Filed: **Nov. 16, 1994**

Intl. Cl. :

C12N 5/00, A61K 48/00, A01N 63/00, C12P 21/06

Current U.S. Cl.:

800/8; 424/93.21; 424/93.7; 435/69.1

Field of Search:

800/2; 435/240.2; 424/93.21

References Cited | [Referenced By]

Other References

Acsadi et al (1991) New Biologist 3, 71-81.

Jacobson et al. (1983) Can. J. Physiol. Pharmacol. 61, 1312-1316.

Steinhelper, M. E., Cochrane, K. L. and Field, L. J., "Hypotension In Transgenic Mice Expressing Atrial Natriuretic Factor Fusion Genes", Hypertension, vol. 16, No. 3, pp. 301-307 (1990).

Development, vol. 110, issued 1990, Y. Lallemand et al., "An in situ Assessment of the Routes and Extents of Colonisation of the Mouse Embryonic Stem Cells and their Descendants", pp. 1241-1248, see entire document.

DNA, vol. 5, No. 5, issued 1986, R. J. MacDonald et al., "Transgenic Progeny Inherit Tissue-Specific Expression of Rat Elastase I Genes", pp. 393-401, see entire document.

Science, vol. 254, issued 1991, Dhawan et al., "Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered Myoblasts", pp. 1509-1512.

Brunner, A. M. et al, "Site-Directed Mutagenesis Of Cysteine Residues In The Pro Region Of The Transforming Growth Factor beta 1 Precursor. Expression And Characterization Of Mutant Proteins," J. Biol. Chem., 264(23):13660-13664, 1989.

Delcarpio, J. B., Lanson, N. A., Jr., Field, L. J. and Claycomb, W. C., "Morphological Characterization Of Cardiomyocytes Isolated From A Transplantable Cardiac Tumor Derived From Transgenic Mouse Atria (AT-1 cells)," Circ. Rsrch., 69:1591-1600, 1991.

Field, L. J., "Atrial Natriuretic Factor-SV40 T Antigen Transgenes Produce Tumors And Cardiac Arrhythmias In Mice," Science, 239:1029-1033, 1988.

Gussoni, E., Pavlath, G. K., Lanctot, A. M., Sharma, K. R., Miller, R. G., Steinman, L. and Blau, H. M., "Normal Dystrophin Transcripts Detected In Duchenne Muscular Dystrophy Patients After Myoblast Transplantation," Nature, 356:435-438, 1992.

Janse, M. J., Cinca, J., Morena, H., Fiolet, J. W., Kleber, A. G., deVries, G. P., Becker, A. E. and Durrer, D., "The Border Zone In Myocardial Ischemia. An Electrophysiological, Metabolic And Histochemical Correlation In The Pig Heart," Circulation Research, 44:576-588, 1979.

Jiao, S., Gurevich, V. and Wolff, J. A., "Long-Term Correction Of Rat Model Of Parkinson's Disease By Gene Therapy", Nature, vol. 362, pp. 450-453 (1993).

Katz, E., Steinhelper, M. E., Daud, A., Delcarpio, J. B., Claycomb, W. C. and Field, L. J. "Cardiomyocyte Proliferation In Mice Expressing .alpha.-Cardiac Myosin Heavy Chain-SV40 T-Antigen Transgenes," Amer. J. Phys., 262 (Heart and Circulatory Physiology 31): H1867-1876, 1992.

Koh, G. Y., Klug, M. G., Soonpaa, M. H., and Field, L. J., "Differentiation And Long-Term Survival of C2C12 Myoblast Grafts In Heart," J. Clin. Invest., vol. 92, Sep. 1993.

Koh, G. Y., Soonpaa, M. H., Klug, M. G. and Field, L. J., "Long-Term Survival Of AT-1 Cardiomyocyte Grafts In Syngeneic Myocardium," Amer. Physiol. Soc., pp. H1727-H1733 (1993).

Loewy, A. D., Bridgman, P. C. and Mettenleiter, T. C., ".beta.-Galactosidase Expressing Recombinant Pseudorabies Virus For Light And Electron Microscopic Study Of Transneuronally Labeled CNS Neurons," Brain Research, 555:346, 1991.

Nadal-Ginard, B., "Commitment, Fusion, And Biochemical Differentiation Of A Myogenic Cell Line In The Absence Of DNA Synthesis," Cell, 15:885-864, 1978.

Rockman, H. A., Ross, R. A., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., Jr. and Chien, K. R., "Segregation Of Atrial-Specific And Inducible Expression Of An ANF Transgene In An in vivo Murine Model Of Cardiac Hypertrophy," Proc. Natl. Acad. Sci., USA, 88:8277-8281, 1991.

Samuel, S. K. et al, "Autocrine Induction Of Tumor Protease Production And Invasion By A Metallothionein-Regulated TGF-beta 1" (Ser223,225), Embo Journal [JC:emb], 11(4):1599-1605, 1992.

Spear, J. F., Michelson, E. L., and More, E. N., "Cellular Electrophysiologic Characteristics Of Chronically Infarcted Myocardium In Dogs Susceptible To Sustained Ventricular Tachyarrhythmias," J. of the Amer. College of Cardiology, 4:1099-1110, 1983.

Steinhelper, M. E., Cochrane, K. L. and Field, L. J., "Hypotension In Transgenic Mice Expressing Atrial Natriuretic Factor Fusion Genes," Hypertension, 16:301-307, 1990.

Steinhelper, M. E. and Field, L. J., "Cardiac Tumors And Dysrhythmias In Transgenic Mice," Toxicologic Pathology, 18:464-469, 1990.

Steinhelper, M. E., Lanson, N., Dresdner, K., Delcarpio, J. B., Wit, A., Claycomb, W. C. and Field, L. J., "Proliferation In Vivo And In Culture Of Differentiated Adult Atrial Cardiomyocytes From Transgenic Mice", Amer. J. Phys., 259 (Heart and Circulatory Physiology 28): H1826-H1834, 1990.

Thompson, L., "Fetal Transplants Show Promise", Science, 257:868-870, 1992.

Yaffe, D., and O. Saxel, "Serial Passaging And Differentiation Of Myogenic Cells Isolated From Dystrophic Mouse Muscle," Nature, 270:725-727, 1977.

Primary Examiner: Crouch; Deborah

Attorney, Agent or Firm: Woodard, Emhardt, Naughton Moriarty & McNett

13 Claims, 1 Drawing Figures



(43 of 59)



US PATENT & TRADEMARK OFFICE

PATENT BIBLIOGRAPHIC DATABASE

Help

Full Text

Boolean

Advanced

Number

Order Copy

PTOLs



(50 of 59)

United States Patent

5,476,996

Wilson, et. al.

Dec. 19, 1995

Human immune system in *non-human* animal

Abstract

Laboratory *non-human* animals in which the immune system of a human donor is induced in and thrives in vivo and expresses the immune response of the human donor in a recipient *non-human* animal, and wherein malignant immune system cells of the human donor can be induced in the recipient *non-human* animal by injection of non-malignant donor cells into the recipient are disclosed.

Inventors: **Wilson; Darcy B.** (La Jolla, CA); **Mosier; Donald E.** (Del Mar, CA).

Assignee: **Lidak Pharmaceuticals** (La Jolla, CA).

Appl. No.: **57,006**

Filed: **May 4, 1993**

Related U.S. Application Data

Continuation of (including streamline cont.) Ser. No. 425,047, Oct. 23, 1989, abandoned, which is a continuation-in-part of Ser. No. 241,590, Sept. 8, 1988, abandoned, which is a continuation-in-part of Ser. No. 207,273, Jun. 14, 1988, abandoned.

Intl. Cl. :

A61K 35/00

Current U.S. Cl.:

800/10; 424/9.1; 424/93.1; 424/93.7; 424/93.71; 424/534; 424/577; 424/578; 800/18

Field of Search:

424/2, 9, 534, 577, 578, 9, 93.1, 93.7, 93.71; 435/240.2; 800/2, DIG. 2, DIG. 5

References Cited | [Referenced By]

U.S. Patent Documents

4,624,917

Nov., 1986

Sugimoto

435/69.1

Foreign Patent Documents

58-23793

Feb., 1983

JP

Primary Examiner: Chambers; Jasmine C.

Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear

5 Claims, 6 Drawing Figures

GOVERNMENT RIGHTS

The research from which this invention arose was supported by grants from the United States

Government (NIH grants: AI-22871, AI-23607, AI-24526, AI-27703 and AI-29182) and the Government has certain rights to the invention under this patent.



(50 of 59)



US PATENT & TRADEMARK OFFICE

PATENT BIBLIOGRAPHIC DATABASE

Help

Full Text

Boolean

Advanced

Number

Order Copy

PTDLs



(59 of 59)

United States Patent

4,736,866

Leder, et. al.

Apr. 12, 1988

Transgenic non-human mammals

Abstract

A transgenic *non-human* eukaryotic animal whose germ cells and somatic cells contain an activated oncogene sequence introduced into the animal, or an ancestor of the animal, at an embryonic stage.

Inventors: **Leder; Philip** (Chestnut Hill, MA); **Stewart; Timothy A.** (San Francisco, CA).

Assignee: **President and Fellows of Harvard College** (Cambridge, MA).

Appl. No.: **623,774**

Filed: **Jun. 22, 1984**

Intl. Cl. :

C12N 1/00, C12Q 1/68, C12N 15/00, C12N 5/00

Current U.S. Cl.:

800/10; 435/6; 435/317.1; 536/23.5; 800/18

Field of Search:

435/6, 172.3, 240, 317, 320, 240.1, 240.2;
935/70, 76, 59, 111, 32; 800/1

References Cited | [Referenced By]

U.S. Patent Documents

<u>4,535,058</u>	Aug., 1985	Weinberg et al.	435/91
<u>4,579,821</u>	Apr., 1986	Palmiter et al.	435/240

Other References

Ucker et al, Cell 27:257-266, Dec. 1981.

Ellis et al, Nature 292:506-511, Aug. 1981.

Goldfarb et al, Nature 296:404-409, Apr. 1981.

Huang et al, Cell 27:245-255, Dec. 1981.

Blair et al, Science 212:941-943, 1981.

Der et al, Proc. Natl. Acad. Sci. USA 79:3637-3640, Jun. 1982.

Shih et al, Cell 29:161-169, 1982.

Gorman et al, Proc. Natl. Acad. Sci. USA 79:6777-6781, Nov. 1982.

Schwab et al, EPA-600/9-82-013, Sym: Carcinogen, Polynucl. Aromat. Hydrocarbons Mar. Environ., 212-32 (1982).

Wagner et al. (1981) Proc. Natl. Acad. Sci USA 78, 5016-5020.

Stewart et al. (1982) Science 217, 1046-8.

Costantini et al. (1981) Nature 294, 92-94.

Lacy et al. (1983) Cell 34, 343-358.

McKnight et al. (1983) Cell 34, 335.

Binster et al. (1983) Nature 306, 332-336.

Palmiter et al. (1982) Nature 300, 611-615.

Palmiter et al. (1983) Science 222, 814.

Palmiter et al. (1982) Cell 29, 701-710.

Primary Examiner: Tanenholtz; Alvin E.

Attorney, Agent or Firm: Clark; Paul T.

12 Claims, 8 Drawing Figures



(59 of 59)